DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
C••••••• C•••• P•••••• I••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
101¢ · 101¢ · 101¢ · 101¢ · 100¢Q2 2025 to Q2 2026
Principal held
at least $200M
sum of BDC pieces, a lower bound
Fair value
$196M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
2
1 equity pieces beside them
Next maturity
Dec 18, 2031
no dated debt inside 24 months
On the tape since
Dec 31, 2024
latest Jun 30, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| A••••• D••• S•••••••• B•• | $200M | 100¢ | -1 pts |
Every BDC piece · 2 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| A••••• D••• S•••••••• B•• | term loan first lien Investment T••• F•••• L••• S•••••• D••• - T••• L••• I••••••• R••• S+500, 0.75% F•••• M•••• | $200M | $197M 100c | SOFR+500 bp |
| A••••• D••• S•••••••• B•• | revolver first lien Investment T••• F•••• L••• S•••••• D••• - R••••••• I••••••• R••• S+500, 0.75% F•••• M••••• | Not disclosed | -$448,000 112c | SOFR+500 bp |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $200M | 100c | SOFR+500 bp | Dec 18, 2031 | 1 |
| first lien revolver first lien | unknown | n/a | SOFR+500 bp | Dec 18, 2031 | 1 |
Equity pieces beside the debt: other ($198M fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $200M | $196M | 100c | 0 |
| Mar 31, 2026 | 1 | $200M | $198M | 101c | 0 |
| Dec 31, 2025 | 1 | $201M | $199M | 101c | 0 |
| Sep 30, 2025 | 1 | $201M | $199M | 101c | 0 |
All 7 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $202M | $200M | 101c | 0 |
| Mar 31, 2025 | 1 | $202M | $198M | 100c | 0 |
| Dec 31, 2024 | 1 | $202M | $198M | 100c | 0 |
What changed
- New borrower on a BDC scheduleDec 31, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- CATALENT CREEKderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it